Search results
Icahn School of Medicine at Mount Sinai Awarded $2 | Newswise
Newswise· 9 hours agoNew York, NY [June 10, 2024]—Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $21 million grant from the National Institute
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Motley Fool via Yahoo Finance· 23 minutes agoBut the market for anti-obesity medicines is vastly larger than the market for MASH drugs. Some...
Florida Atlantic University Lab Schools secure $2M for new research center
The Palm Beach Post· 5 hours agoThe center will host visiting scholars and researchers, as well as advance current research at the...
Inside Look: Women’s Health Health Lab 2024
Women's Health via Yahoo News· 7 days agoThis year’s event, in partnership with Northwell’s Katz Institute for Women’s Health, featured an array of exciting voices helping change the landscape...
Chronotherapy: Why Timing Drugs to Our Body Clocks May Work
Medscape· 9 hours agoA new analysis published in this month's issue of The Lancet journal's eClinicalMedicine suggests:...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 7 hours agoIndia Breakthrough: Bio Regenerative Precision Medicine Seminar Held in Hyderabad PR Newswire HYDERABAD, India, June 10, 2024 HYDERABAD, India, June 10, 2024 /PRNewswire/ ...
Valentin Fuster, MD, PhD, Received 2024 Distinguis | Newswise
Newswise· 9 hours agoNewswise — (New York, NY – June 10, 2024) – The European Society for Clinical Investigation (ESCI) is awarding Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief ...
NVIDIA and top VC firms invest in Vilya, a biotech spinout from Seattle’s Institute for Protein...
GeekWire· 6 days agoVilya, a biotech startup built off technology developed at the Seattle-based Institute for Protein...
A conversation with Ann B. Barshinger Cancer Institute's award winning executive medical director
Lancaster Online· 4 days agoAfter more than 40 years practicing medicine, Dr. Randall A. Oyer still shows up to work around 5:30...
Iomab-B shows promise in high-risk leukemia treatment By Investing.com
Investing.com· 1 hour agoThe Phase 3 SIERRA trial data indicated that Iomab-B, a targeted radiotherapy, met its primary...
